About Immudex
Immudex is a company based in Copenhagen (Denmark) founded in 2009. Immudex has raised $16.35 million across 12 funding rounds. Immudex offers products and services including Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T. Immudex operates in a competitive market with competitors including HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Kypha, among others.
- Headquarter Copenhagen, Denmark
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immudex Aps
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.35 M (USD)
in 12 rounds
-
Latest Funding Round
$290.6 K (USD), Series A
Feb 10, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immudex
Immudex offers a comprehensive portfolio of products and services, including Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T.
Reagents for detecting antigen-specific T cells via flow cytometry.
Tools for T cell activation and expansion in research.
Products for customizable immune monitoring applications.
Reagents for detecting CAR cells in therapies.
System for mimicking TCR immunological synapse.
People of Immudex
Unlock access to complete
Unlock access to complete
Funding Insights of Immudex
Immudex has successfully raised a total of $16.35M across 12 strategic funding rounds. The most recent funding activity was a Series A round of $290.6 thousand completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Immudex
Investment portfolio details for Immudex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immudex
Detailed financials for Immudex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immudex Comparisons
Peer comparison for Immudex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immudex
Immudex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HYCOR BioMedical, Exagen, Lophius Biosciences, PredictImmune and Kypha, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| Locked | Locked | Locked |
Diagnostic and monitoring solutions for autoimmune connective diseases are developed.
|
|
| Locked | Locked | Locked |
T-cell-based diagnostics for infectious and immune diseases are developed.
|
|
| Locked | Locked | Locked |
Tools for diagnosing immune-mediated inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Diagnostic biomarker tests for inflammation and autoimmune diseases are developed.
|
Detailed competitors of Immudex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immudex
Complete news archive for Immudex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immudex
Immudex was founded in 2009.
Immudex is headquartered in Copenhagen, Denmark.
Patrik Dahlen is the current CEO of Immudex.
Immudex is a funded company, having raised a total of $16.35M across 12 funding rounds to date.
Provider of immune monitoring reagents and services for research and clinical use. It offers a portfolio of products, including dextramer reagents for flow cytometry and other applications, Klickmer reagents, and custom solutions. The products are used to detect and characterize antigen specific immune cells, supporting research in areas such as vaccine development, cell therapy, and infectious disease. It also provides services such as custom allele production and proficiency testing. Its offerings enable researchers and clinicians to gain a deeper understanding of the immune response in various contexts.It provides a range of products and services such as Dextramer and dcode MHC multimers for detailed immune profiling, clinical grade reagents, monomers and U- Load reagents, techincal and scientfic support, and more.
Immudex's top competitors include Exagen, SmartHealth and HYCOR BioMedical.
Immudex offers Dextramer®, Klickmer®, U-Load®, CAR Dextramer®, and Xynapse™-T.
The valuation of Immudex is $15.11M as of Feb 2025.